Want to see AU:HXL full AI Analyst Report?
HXL Stock Chart & Stats
AU$0.01
AU$0.00(0.00%)
At close: 4:00 PM EDT
AU$0.01
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.01
Previous CloseN/A
Volume15.80K
Average Volume (3M)0.00
Market Cap
AU$2.17M
Enterprise ValueAU$0.77
Total Cash (Recent Filing)AU$1.54M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta-0.08
Next Earnings
Feb 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding41,759,846
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.36
Price to Sales (P/S)0.00
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$45.80M
Bulls Say, Bears Say
Bulls Say
Low LeverageA near-zero debt position materially reduces refinancing and interest-rate risk, giving management runway to fund development or absorb setbacks. For a cash-burning biotech, low leverage preserves strategic optionality for partnerships or milestone-based financing over the next several months.
Proprietary Defensin PlatformA technology platform based on plant defensins provides a durable competitive advantage: it supports multiple candidate programs, creates higher barriers to entry, and enables leverage across indications. Platform IP underpins longer-term value if clinical progress or partnerships materialize.
Improving Cash Burn Trend In 2025A reduction in annual cash outflows and narrower losses signals better cost control or program prioritization. That trend, if sustained, lengthens runway and reduces near-term dependency on dilutive financing, improving the firm's ability to execute clinical or partnership milestones over months.
Bears Say
Persistent Operating LossesChronic negative EBIT and net losses erode equity and limit internal capital generation. Over the medium term this constrains funding options, forces management to rely on external financing or dilution, and raises execution risk for advancing clinical programs to value-inflecting milestones.
Near-zero RevenueA collapse to negligible revenue indicates weak commercialization or reliance on non-recurring income. Without sustainable sales, funding must come from capital markets or partners, increasing execution risk and making long-term viability dependent on successful trials or strategic deals.
Consistent Negative Cash FlowPersistent negative operating and free cash flow reflect structural cash burn typical of pre-revenue biotech. Continued outflows necessitate funding rounds or partnerships, which can dilute shareholders and divert management focus from R&D to financing, raising medium-term execution risk.
Hexima Ltd News
HXL FAQ
What was Hexima Ltd’s price range in the past 12 months?
Hexima Ltd lowest share price was AU$0.01 and its highest was AU$0.01 in the past 12 months.
What is Hexima Ltd’s market cap?
Hexima Ltd’s market cap is AU$2.17M.
When is Hexima Ltd’s upcoming earnings report date?
Hexima Ltd’s upcoming earnings report date is Feb 26, 2027 which is in 182 days.
How were Hexima Ltd’s earnings last quarter?
Currently, no data Available
Is Hexima Ltd overvalued?
According to Wall Street analysts Hexima Ltd’s price is currently Overvalued.
Does Hexima Ltd pay dividends?
Hexima Ltd pays a N/A dividend of AU$0.002 which represents an annual dividend yield of N/A. See more information on Hexima Ltd dividends here
What is Hexima Ltd’s EPS estimate?
Hexima Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hexima Ltd have?
Hexima Ltd has 41,759,846 shares outstanding.
What happened to Hexima Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Hexima Ltd?
Currently, no hedge funds are holding shares in AU:HXL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hexima Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.00%
12-Months-Change
Fundamentals
Return on Equity
0.00%
Trailing 12-Months
Asset Growth
-14.34%
Trailing 12-Months
Company Description
Hexima Ltd
Hexima Limited is a biotechnology firm focused on the discovery and advancement of plant-derived proteins and peptides for medical applications in humans. Its primary drug candidate, pezadeftide, a plant defensin, is presently undergoing Phase IIb clinical evaluations in Australia and New Zealand to address fungal toenail infections. The company was established in 1997 and its main operations are situated in Preston, Australia.
Technical Analysis
Acrux
―
Starpharma Holdings Limited
―
Tissue Repair Ltd
―
Botanix Pharmaceuticals Limited
―
Recce Pharmaceuticals Ltd.
―